Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01017458 | Safety and Tolerability of MK0773 in Healthy Older Men (0773-004) | PHASE1 | COMPLETED | 68 | — | — | Jun 1, 2007 | Aug 1, 2008 | Jul 12, 2016 | - | — |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | MK0773 + placebo injection |
| 2 | ACTIVE_COMPARATOR | placebo to MK0773 + testosterone injection |
| 3 | PLACEBO_COMPARATOR | placebo to MK0773 + placebo injection |
| Name | Type | Description |
|---|---|---|
| MK0773 | DRUG | Three 25mg oral tablets MK0773 bid, for 12 weeks |
| Comparator: testosterone enanthate | DRUG | intramuscular injection 200mg testosterone enanthate q14d, for 12 weeks |
| Comparator: placebo oral tablet | DRUG | placebo oral tablet bid, for 12 weeks |
| Comparator: placebo injection | DRUG | placebo intramuscular injection q14d, for 12 weeks |
Inclusion Criteria: * Subject is in good general health * Subject agrees to avoid excess alcohol and strenuous physical activity during the study * Subject who is sexually active with partners of reproductive potential agrees to use two forms of appropriate contraception during the study Exclusion...